New report

Advanced development of primary pancreatic organoid tumor models for high-throughput phenotypic drug screening

A multidisciplinary team of scientists share recent advancements in innovative in-vitro cancer biology methods for screening drug-like molecules in cancer tissue relevant models in a new report published online ahead-of-print at SLAS Discovery.

Photo
PANC-1 Spheroid
Source: Shurong Hou, Ph.D.

A multidisciplinary team of scientists share recent advancements in innovative in-vitro cancer biology methods for screening drug-like molecules in cancer tissue relevant models in a new report published online ahead-of-print at SLAS Discovery. Entitled Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening, the report can be accessed for free.

The authors -- Senior Scientific Directors Timothy Spicer and Louis Scampavia and Post-Doctoral Associate Shurong Hou at Scripps Florida in collaboration with Cold Spring Harbor Laboratory, Greiner Bio-One, Nano3D Biosciences, Inc., University of Texas Health Science Center at Houston, and the Dana-Farber Cancer Institute -- illustrate how a magnetic nanoparticle assembly approach is used to increase throughput dramatically while reducing costs. This technology combines specialized high-density microtiter plates formulated with an ultra-low attachment surface along with gold nanoparticles (nanoshuttles), which are used to label cancer cells in-vitro. Once labeled, a magnetic driver quickly pulls the cells into a 3D spheroid or organoid structure. This 3D structure is retained and drug–like molecules can then be added, affording the ability to ascertain their efficacy.

With the advent of cost-effective and high-throughput 3D tissue culture, the importance of developing this technology using patient-derived cancer cells is to ensure a more disease and physiologically relevant point of comparison to 2D monolayer testing, thereby validating the hypothesis of 3D relevance as a predictor of possible patient outcomes. This allows researchers to step closer to identifying patient-specific therapies and points in the direction of rapid 3D testing of patient-derived cancer cells against FDA-approved drugs, which may be both affordable and amenable for a precision medicine approach to provide timely and critical feedback to physicians.


Source: SLAS (Society for Laboratory Automation and Screening)

20.04.2018

Read all latest stories

Related articles

Biomarker validation

Plodding toward a pancreatic cancer screening test

Pancreatic cancer is one of the most deadly types of malignancies, with a 5-year survival rate after late diagnosis of only about 5%. The majority of patients—about 80%—receive their diagnosis…

Photoacoustics

New method shows 3D images of cancer cells in the body

Making tumour cells glow: Medical physicists at Martin Luther University Halle-Wittenberg (MLU) have developed a new method that can generate detailed three-dimensional images of the body's interior.…

High throughput screening

Tumor-like spheres to help discover smarter cancer drugs

Cancer is a disease often driven by mutations in genes. As researchers learn more about these genes, and the proteins they code for, they are seeking smarter drugs to target them. The ultimate goal…

Related products

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

RIS/PACS

medigration - RIS / PACS

medigration GmbH

Research use only (RUO)

SARSTEDT - Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG

Research use only (RUO)

Shimadzu - CLAM-2000

Shimadzu Europa GmbH

RIS/PACS

Siemens Healthineers - syngo.plaza

Siemens Healthineers

RIS / PACS

Siemens Healthineers - syngo.via

Siemens Healthineers